Precigen Inc
NASDAQ:PGEN

Watchlist Manager
Precigen Inc Logo
Precigen Inc
NASDAQ:PGEN
Watchlist
Price: 3.51 USD -4.88% Market Closed
Market Cap: 1.2B USD

Precigen Inc
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Precigen Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Precigen Inc
NASDAQ:PGEN
Revenue
$6.3m
CAGR 3-Years
-40%
CAGR 5-Years
-43%
CAGR 10-Years
-28%
Abbvie Inc
NYSE:ABBV
Revenue
$59.6B
CAGR 3-Years
1%
CAGR 5-Years
8%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$29.1B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
-1%
Amgen Inc
NASDAQ:AMGN
Revenue
$36B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$11.7B
CAGR 3-Years
10%
CAGR 5-Years
14%
CAGR 10-Years
31%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$14.2B
CAGR 3-Years
1%
CAGR 5-Years
12%
CAGR 10-Years
14%
No Stocks Found

Precigen Inc
Glance View

Market Cap
1.2B USD
Industry
Biotechnology

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The company is headquartered in Germantown, Maryland and currently employs 456 full-time employees. The company went IPO on 2013-08-08. Its therapeutic platforms, including UltraCAR-T, AdenoVerse immunotherapy, and ActoBiotics, are designed to precisely control the level and physiological location of gene expression and modify biological molecules to control the function and output of living cells to treat underlying disease conditions. The Company’s lead clinical programs, including: PRGN-3005, PRGN-3006, and PRGN-3007, which are built on its UltraCAR-T platform; PRGN-2009 and PRGN-2012, which are based on its AdenoVerse immunotherapy platform; and AG019, which is built on its ActoBiotics platform. The firm also completed a Phase I study of INXN-4001, a non-viral triple-effector plasmid DNA, which is built on its UltraVector platform. The company also has a robust pipeline of preclinical programs.

PGEN Intrinsic Value
HIDDEN
Show

See Also

What is Precigen Inc's Revenue?
Revenue
6.3m USD

Based on the financial report for Sep 30, 2025, Precigen Inc's Revenue amounts to 6.3m USD.

What is Precigen Inc's Revenue growth rate?
Revenue CAGR 10Y
-28%

Over the last year, the Revenue growth was 59%. The average annual Revenue growth rates for Precigen Inc have been -40% over the past three years , -43% over the past five years , and -28% over the past ten years .

Back to Top